Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity

References

• Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793–801. DOI:10.1016/S1074-7613(94)80021-9
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–1217. DOI:10.1084/jem.20112741
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. DOI:10.3390/cancers12030738
   PubMed Web of Science ®Google Scholar
• Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895. DOI:10.1084/jem.20051776
   PubMed Web of Science ®Google Scholar
• Janakiram M, Shah UA, Liu W, et al. The third group of the B7- CD 28 immune checkpoint family: hHLA 2, TMIGD 2, B7x, and B7-H3. Immunol Rev. 2017;276(1):26–39. DOI:10.1111/imr.12521
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. DOI:10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. DOI:10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. DOI:10.1056/NEJMoa1805131
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–Positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. DOI:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. DOI:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. DOI:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604. DOI:10.1016/S0140-6736(21)00228-2
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. DOI:10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Halmos B, Burke T, Kalyvas C, et al. Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy±bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison. Lung Cancer. 2021;155:175–182.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846. DOI:10.1016/S0140-6736(16)00587-0
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322. DOI:10.1016/S1470-2045(17)30065-7
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–2114. DOI:10.1056/NEJMoa2034442
   PubMed Web of Science ®Google Scholar
• Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044–3050. DOI:10.1093/annonc/mdx518
   PubMed Web of Science ®Google Scholar
• Keilholz U, Mehnert JM, Bauer S, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2019;7(1):12. DOI:10.1186/s40425-018-0459-y
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. DOI:10.1056/NEJMoa2002788
   PubMed Web of Science ®Google Scholar
• Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–3125. DOI:10.1200/JCO.2016.67.9761
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. DOI:10.1016/S1470-2045(16)30066-3
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. DOI:10.1056/NEJMoa1602252
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. DOI:10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203. DOI:10.1056/NEJMoa2032125
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. DOI:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. DOI:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. DOI:10.1056/NEJMoa2017699
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. DOI:10.1136/jitc-2021-003777
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. DOI:10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643–654. DOI:10.1016/S1470-2045(21)00065-6
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–694. DOI:10.1056/NEJMoa2106391
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):1270–1271.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. DOI:10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. DOI:10.1016/S1470-2045(16)30098-5
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. DOI:10.1016/S0140-6736(20)32714-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. DOI:10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Yau T, Park J-W, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. DOI:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178–1188. DOI:10.1038/s41591-022-01851-x
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Sugiura D, Okazaki I, et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2):e001014. DOI:10.1136/jitc-2020-001014
   PubMed Web of Science ®Google Scholar
• Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176–189. DOI:10.18632/genesandcancer.180
   PubMedGoogle Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. DOI:10.1056/NEJMoa2109970
   PubMed Web of Science ®Google Scholar
• Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927. DOI:10.1158/0008-5472.CAN-11-1620
   PubMed Web of Science ®Google Scholar
• Sauer N, Szlasa W, Jonderko L, et al. LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors. Int J Mol Sci. 2022;23(17):9958. DOI:10.3390/ijms23179958
   PubMed Web of Science ®Google Scholar
• Jiang H, Ni H, Zhang P, et al. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology. 2021;10(1):1943180. DOI:10.1080/2162402X.2021.1943180
   PubMed Web of Science ®Google Scholar
• Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. DOI:10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. DOI:10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. DOI:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985. DOI:10.1056/NEJMoa2202170
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211. DOI:10.1016/S1470-2045(20)30641-0
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. DOI:10.1016/S2213-2600(19)30084-0
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. DOI:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. DOI:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. DOI:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Lee C-H, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021;22(7):946–958. DOI:10.1016/S1470-2045(21)00241-2
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. DOI:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. DOI:10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. DOI:10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. DOI:10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Cottrell T, Taube JM. PD-L1 and emerging biomarkers in PD-1/PD-L1 blockade therapy. Cancer J. 2018;24(1):41–46.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Yu J, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083. DOI:10.1038/s41598-020-58674-4
   PubMed Web of Science ®Google Scholar
• Grasso CS, Tsoi J, Onyshchenko M, et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2020;38(4):500–515.e3. DOI:10.1016/j.ccell.2020.08.005
   PubMed Web of Science ®Google Scholar
• Johnson DB, Bordeaux J, Kim JY, et al. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti–PD-1 therapies in metastatic melanoma. Clin Cancer Res. 2018;24(21):5250–5260. DOI:10.1158/1078-0432.CCR-18-0309
   PubMed Web of Science ®Google Scholar
• Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7(1):10582. DOI:10.1038/ncomms10582
   PubMedGoogle Scholar
• Postow MA, Hellmann MD, Adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(12):158–168. DOI:10.1056/NEJMra1703481
   PubMedGoogle Scholar
• Becerra MVS, Martinez-Cabañes R, Gonzalez-Lopez A, et al. 204P Immune-related adverse events (IrAes) as a predictor of response to immunotherapy in patients with lung cancer. J Thorac Oncol. 2021;16:S808–809.
   Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. JCO. 2017;35(7):785–792. DOI:10.1200/JCO.2015.66.1389
   PubMed Web of Science ®Google Scholar
• Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – a systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.
   PubMed Web of Science ®Google Scholar
• Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–1212. DOI:10.1001/jamadermatol.2015.1916
   PubMed Web of Science ®Google Scholar
• Quach HT, Dewan AK, Davis EJ, et al. Association of anti–programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 2019;5(6):906–908. DOI:10.1001/jamaoncol.2019.0046
   PubMed Web of Science ®Google Scholar
• Tang K, Seo J, Tiu BC, et al. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 therapy. JAMA Dermatol. 2022;158(2):189–193. DOI:10.1001/jamadermatol.2021.5476
   PubMed Web of Science ®Google Scholar
• Dousset L, Pacaud A, Barnetche T, et al. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: a cross-sectional study. JAAD Int. 2021;5:112–120.
   PubMedGoogle Scholar
• Nakano E, Takahashi A, Namikawa K, et al. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: a single institutional retrospective study. J Dermatol. 2020;47(6):622–628. DOI:10.1111/1346-8138.15309
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. DOI:10.1126/science.aan4236
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–108. DOI:10.1126/science.aao3290
   PubMed Web of Science ®Google Scholar
• Routy B, Gopalakrishnan V, Daillère R, et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15(6):382–396. DOI:10.1038/s41571-018-0006-2
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study. Sci Rep. 2019;9(1):2447. DOI:10.1038/s41598-019-39120-6
   PubMedGoogle Scholar
• McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322. DOI:10.1016/S1470-2045(18)30078-0
   PubMed Web of Science ®Google Scholar
• Rogado J, Romero-Laorden N, Sanchez-Torres JM, et al. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. Oncoimmunology. 2020;9(1):1751548. DOI:10.1080/2162402X.2020.1751548
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–562.
   PubMed Web of Science ®Google Scholar
• Miller BC, Sen DR, Abosy RA, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326–336. DOI:10.1038/s41590-019-0312-6
   PubMed Web of Science ®Google Scholar
• Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–421. DOI:10.1038/nature19330
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhou Y, Zhang X, et al. Immune checkpoint inhibitors in the treatment of patients with cancer and preexisting psoriasis: a systematic review and meta-analysis of observational studies. Front Oncol. 2022;12:934093.
   PubMedGoogle Scholar
• Alexander S, Swami U, Kaur A, et al. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med. 2021;9(12):1033. DOI:10.21037/atm-20-8124
   PubMed Web of Science ®Google Scholar
• Higgins JP, Trinh AV, Watson ML, et al. A safety analysis of programmed death 1 pathway inhibitors in patients with solid tumor malignancies and preexisting autoimmune disease. J Clin Rheumatol. 2022;28(7):338–345. DOI:10.1097/RHU.0000000000001863
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Chen T-W, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385. DOI:10.1093/annonc/mdx286
   PubMed Web of Science ®Google Scholar
• Yan Y-D, Zhao Y, Zhang C, et al. Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system. eClinicalmedicine. 2022;50:101535.
   PubMedGoogle Scholar
• Tarhini AA, Lee SJ, Hodi FS, et al. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon Alfa-2b for resected high-risk melanoma: north American intergroup E1609. J Clin Oncol. 2020;38(6):567–575. DOI:10.1200/JCO.19.01381
   PubMed Web of Science ®Google Scholar
• Lebbé C, Meyer N, Mortier L, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol. 2019;37(11):867–875. DOI:10.1200/JCO.18.01998
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. DOI:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265–1274. DOI:10.1016/S1470-2045(21)00333-8
   PubMed Web of Science ®Google Scholar
• Park R, Lopes L, Cristancho CR, et al. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Front Oncol. 2020;10 [[cited 2022 Sep 25]]. InternetAvailable from: https://www.frontiersin.org/articles/10.3389/fonc.2020.00258
   Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. DOI:10.1056/NEJMoa1709684
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. DOI:10.1001/jamaoncol.2018.3923
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. JCO. 2012;30(21):2691–2697.
   PubMed Web of Science ®Google Scholar
• Tang S-Q, Tang L-L, Mao Y-P, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat. 2021;53(2):339–354. DOI:10.4143/crt.2020.790
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. DOI:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer. JAMA Oncol. 2019;5(7):1043–1047. DOI:10.1001/jamaoncol.2019.0402
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. DOI:10.1126/scitranslmed.3008002
   PubMed Web of Science ®Google Scholar
• Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019;25(8):1243–1250. DOI:10.1038/s41591-019-0523-2
   PubMed Web of Science ®Google Scholar
• Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving Anti-PD-1–based immunotherapy. Clin Cancer Res. 2019;25(5):1557–1563. DOI:10.1158/1078-0432.CCR-18-2795
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Numakura K, Hatakeyama S, et al. Severe immune-related adverse events in patients treated with nivolumab for metastatic renal cell carcinoma are associated with PDCD1 polymorphism. Genes (Basel). 2022;13(7):1204. DOI:10.3390/genes13071204
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. DOI:10.1038/s41571-022-00600-w
   PubMed Web of Science ®Google Scholar
• Mor A, Strazza M. Bridging the gap: connecting the mechanisms of immune-related adverse events and autoimmunity through PD-1. Front Cell Dev Biol. 2022;9. [[cited 2022 Sep 23]]. InternetAvailable from: https://www.frontiersin.org/articles/10.3389/fcell.2021.790386
   PubMed Web of Science ®Google Scholar
• Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715–720. DOI:10.1172/JCI96798
   PubMed Web of Science ®Google Scholar
• von Itzstein MS, Khan S, Gerber DE, et al. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem. 2020;66(6):779–793.
   PubMed Web of Science ®Google Scholar
• Schindler K, Harmankaya K, Kuk D, et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. JCO. 2014;32(15_suppl):9096. DOI:10.1200/jco.2014.32.15_suppl.9096
   Web of Science ®Google Scholar
• Bastacky ML, Wang H, Fortman D, et al. Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis. Front Oncol. 2021;11:749064.
   PubMedGoogle Scholar
• Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109(11):3583–3590. DOI:10.1111/cas.13800
   PubMed Web of Science ®Google Scholar
• Ghosh N, Postow M, Zhu C, et al. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. J Immunother Cancer. 2022;10(1):e004008. DOI:10.1136/jitc-2021-004008
   PubMed Web of Science ®Google Scholar
• Castel-Ajgal Z, Goulvestre C, Zaibet S, et al. Preexisting autoantibodies and immune related adverse events in metastatic urothelial carcinoma patients treated by pembrolizumab. Clinical Genitourinary Cancer [Internet]. 2022 [cited 2022 Aug 11]; Available from: https://www.sciencedirect.com/science/article/pii/S1558767322000799.
   Google Scholar
• Andrews MC, Duong CPM, Gopalakrishnan V, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021;27(8):1432–1441. DOI:10.1038/s41591-021-01406-6
   PubMed Web of Science ®Google Scholar
• Simpson RC, Shanahan ER, Batten M, et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022;28(11):2344–2352.
   Web of Science ®Google Scholar
• Owen CN, Bai X, Quah T, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021;32(7):917–925. DOI:10.1016/j.annonc.2021.03.204
   PubMed Web of Science ®Google Scholar
• Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7(1):165. DOI:10.1186/s40425-019-0645-6
   PubMedGoogle Scholar
• Lozano AX, Chaudhuri AA, Nene A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28(2):353–362. DOI:10.1038/s41591-021-01623-z
   PubMed Web of Science ®Google Scholar
• Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). JCO. 2022;41(3):517–527. JCO.22.00533.
   PubMed Web of Science ®Google Scholar
• Jing Y, Yang J, Johnson DB, et al. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol. 2022;19(4):269–280. DOI:10.1038/s41571-021-00597-8
   PubMed Web of Science ®Google Scholar
• Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591–5598. DOI:10.1158/1078-0432.CCR-09-1024
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509–523.e6. DOI:10.1016/j.ccell.2022.04.004
   PubMed Web of Science ®Google Scholar
• Dimitriou F, Hogan S, Menzies AM, et al. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer. 2021;157:214–224.
   PubMed Web of Science ®Google Scholar
• Darnell EP, Mooradian MJ, Baruch EN, et al. Immune-related adverse events (irAes): diagnosis, management, and clinical pearls. Curr Oncol Rep. 2020;22(4):39. DOI:10.1007/s11912-020-0897-9
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–142.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–241. DOI:10.6004/jnccn.2020.0012
   PubMed Web of Science ®Google Scholar
• Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events | Journal for ImmunoTherapy of Cancer [Internet]. [cited 2022 Sep 25]. Available from: https://jitc.bmj.com/content/9/6/e002435
   Google Scholar
• Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update | Journal of Clinical Oncology [Internet]. [cited 2022 Sep 25]. Available from: https://ascopubs-org.proxy.library.vanderbilt.edu/doi/full/10.1200/JCO.21.01440
   Google Scholar
• Common terminology criteria for adverse events (CTCAE). 2017;p. 155.
   Google Scholar
• Johnson DB, Reynolds KL, Sullivan RJ, et al. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol. 2020;21(8):e398–404. DOI:10.1016/S1470-2045(20)30107-8
   PubMed Web of Science ®Google Scholar
• Luo J, Beattie JA, Fuentes P, et al. Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events. J Thorac Oncol. 2021;16(10):1759–1764. DOI:10.1016/j.jtho.2021.06.024
   PubMed Web of Science ®Google Scholar
• Beattie J, Rizvi H, Fuentes P, et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021;9(2):e001884. DOI:10.1136/jitc-2020-001884
   PubMed Web of Science ®Google Scholar
• Dougan M, Blidner AG, Choi J, et al. Multinational association of support care cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Cancer Ther. 2020;28(12):6129–6143. DOI:10.1007/s00520-020-05707-3
   PubMed Web of Science ®Google Scholar
• Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6(1):103. DOI:10.1186/s40425-018-0412-0
   PubMed Web of Science ®Google Scholar
• Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer. 2022;10(4):e004699. DOI:10.1136/jitc-2022-004699
   PubMed Web of Science ®Google Scholar
• Salem J-E, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor–associated myocarditis. N Engl J Med. 2019;380(24):2377–2379. DOI:10.1056/NEJMc1901677
   PubMed Web of Science ®Google Scholar
• Wei SC, Meijers WC, Axelrod ML, et al. A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021;11(3):614–625. DOI:10.1158/2159-8290.CD-20-0856
   PubMed Web of Science ®Google Scholar
• Jiang C, Zhang L, Xu X, et al. Engineering a smart agent for enhanced immunotherapy effect by simultaneously blocking PD‐L1 and CTLA‐4. Adv Sci. 2021;8(20):2102500. DOI:10.1002/advs.202102500
   Web of Science ®Google Scholar
• Gan X, Shan Q, Li H, et al. An anti-CTLA-4 heavy chain–only antibody with enhanced treg depletion shows excellent preclinical efficacy and safety profile. Proc Natl Acad Sci USA. 2022;119(32):e2200879119.
   Google Scholar
• Chung CK, Fransen MF, van der Maaden K, et al. Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies. JControlled Release. 2020;323:1–11.
   PubMed Web of Science ®Google Scholar
• Guo M, VanderWalde AM, Yu X, et al. Immune checkpoint inhibitor rechallenge safety and efficacy in stage IV non-small cell lung cancer patients after immune-related adverse events. Clin Lung Cancer. 2022;23:686–693.
   PubMed Web of Science ®Google Scholar
• Yang J, Zeng R, Zhou J, et al. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. Transl Lung Cancer Res. 2022;11(6):1038–1050. DOI:10.21037/tlcr-22-360
   PubMed Web of Science ®Google Scholar
• Ngamphaiboon N, Ithimakin S, Siripoon T, et al. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. BMC Cancer. 2021;21(1):1275. DOI:10.1186/s12885-021-09003-z
   PubMed Web of Science ®Google Scholar
• Albandar HJ, Fuqua J, Albandar JM, et al. Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to rechallenge or not? Cancers (Basel). 2021;13(5):989. DOI:10.3390/cancers13050989
   PubMed Web of Science ®Google Scholar
• Allouchery M, Lombard T, Martin M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8(2):e001622. DOI:10.1136/jitc-2020-001622
   PubMed Web of Science ®Google Scholar